Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference
Impel NeuroPharma (NASDAQ: IMPL) will have its Chairman and CEO, Adrian Adams, participate in a fireside chat during the Guggenheim Securities 3rd Annual Neuro/Immunology Conference on November 16, 2021, at 1:40 p.m. ET. A live webcast will be available on the company’s investor website, with a replay accessible afterward. Impel NeuroPharma focuses on developing innovative therapies for central nervous system diseases, including the approved Trudhesa™ for migraines and ongoing development of INP105 and INP107 for autism-related agitation and Parkinson’s OFF episodes.
- None.
- None.
SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system (CNS), today announced that Adrian Adams, Chairman and CEO, will participate in a fireside chat at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference on Tuesday, November 16, 2021 at 1:40 p.m. ET.
A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the presentation will be available on the Impel NeuroPharma website following the event.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
Investor Relations:
Christina Tartaglia
Stern Investor Relations
Phone: (1) 212-362-1200
Email: christina.tartaglia@sternir.com
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com
FAQ
When is Adrian Adams speaking at the Guggenheim Securities Conference for Impel NeuroPharma (IMPL)?
How can I watch the Impel NeuroPharma (IMPL) conference presentation?
What therapies does Impel NeuroPharma (IMPL) focus on developing?
What is Trudhesa™ from Impel NeuroPharma (IMPL)?
